Phaseline

Targets › FGF21

FGF21 (Fibroblast growth factor 21): drug programs, companies and trials

3 programs from 3 companies in 10 trials: 7 Phase 3, 2 Phase 2, 1 Phase 1; Gastroenterology, Metabolic and endocrine; next expected readout Dec 2026.

Stimulates glucose uptake in differentiated adipocytes via the induction of glucose transporter SLC2A1/GLUT1 expression (but not SLC2A4/GLUT4 expression). Activity requires the presence of KLB. Regulates systemic glucose homeostasis and insulin sensitivity. (UniProt, Q9NSA1)

Open in Phaseline: the race on FGF21, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
GSKEfimosfermin alfa
FGF21 analog
FGF21Phase 3Non-alcoholic Fatty Liver Disease; Metabolic Dysfunction-associated Steatohepatitis; Liver Diseases, AlcoholicOct 2027
Akero TherapeuticsEfruxifermin
FGF21 receptor agonist
FGF21Phase 3NASH/MASH; NASH - Nonalcoholic Steatohepatitis; NASH With FibrosisFeb 2030
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin PharmaceuticalTQA2225/AP025
FGF21-Fc fusion protein
FGF21Phase 2Non-alcoholic SteatohepatitisDec 2026

Conditions

Non-alcoholic Fatty Liver Disease (3) Metabolic Dysfunction-associated Steatohepatitis (2) NASH/MASH (1) NASH - Nonalcoholic Steatohepatitis (1) NASH With Fibrosis (1) Liver Diseases, Alcoholic (1) Non-alcoholic Steatohepatitis (1)

Modalities

protein or peptide (2)

Companies

Akero Therapeutics (1) GSK (1) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.